Daniel M. Blumberger, MD, MSc

  • 11Articles
  • 64.9KReads
  • 2014–2025Active
  • 51Collaborators
  • 392Citations

About

Daniel M. Blumberger, MD, MSc is affiliated with Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. Daniel M. Blumberger has authored or co-authored 11 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2014 and 2025. Their work focuses on Depression (MDD), Suicide, Electroconvulsive Therapy, Anxiety, and Anxiolytics.

Publications

JCP
ECT for Psychotic vs Nonpsychotic Depression
Original Research

ECT for Psychotic vs Nonpsychotic Depression

January 29, 2025

Patients with major depression with psychotic features had higher response rates to ECT than those without psychotic features and similar rates of adverse cognitive effects. After adjustment for confounders,...
, , , et al
JCP
Inpatient Treatment of Suicidality
Systematic Review

Inpatient Treatment of Suicidality

January 8, 2025

Effective, rapid treatments that target suicidality in psychiatric inpatients are scarce in the existing literature and in clinical practice, underscoring the need for studies to identify and validate these...
, , , et al
JCP
rTMS for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies
Commentary

rTMS for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies

April 26, 2023

The authors argue that insurance companies’ prior authorization process overly restricts access to rTMS, which has proven effectiveness for TRD.
, , , et al
JCP
Meta-Analysis

Effect of rTMS on Suicidal Ideation in Treatment-Resistant Depression

January 18, 2022

Repetitive magnetic transcranial stimulation (rTMS) has been established as an efficacious treatment for MDD. This meta-analysis looked at its effects on suicidal ideation in depressed patients across the lifespan.
, , , et al
JCP
Original Research

Continuation MST for Treatment-Resistant Depression

October 19, 2021

Magnetic seizure therapy (MST) has shown promise as an alternative to electroconvulsive therapy for acute treatment-resistant depression (TRD). This study examines the efficacy of MST as a continuation treatment...
, , , et al
JCP
Original Research

Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depression

September 29, 2020

This analysis of data from 2 clinical trials examined the effect of benzodiazepines on outcomes in older patients with generalized anxiety disorder or major depressive disorder, including the likelihood...
, , , et al
JCP
Original Research

Predicting Remission in Late-Life Depression

December 10, 2019

Rates of treatment resistance in randomized controlled trials in patients with late-life depression are as high as 77% using SSRIs, yet SSRIs are often used as first-line treatment. This...
, , , et al
JCP
Original Research

Predictors of Extrapyramidal Symptoms With Aripiprazole in Late-Life Depression

June 19, 2018

Augmentation of antidepressants with aripiprazole is effective in treating late-life depression. As an antipsychotic medication, however, aripiprazole potentially leads to extrapyramidal side effects (EPS). Read this article to learn...
, , , et al
JCP
Original Research

Does rTMS Decrease Suicidal Ideation?

April 17, 2018

Read a study on the effects of rTMS on suicidal ideation in patients with treatment-resistant major depression (TRD).
, , , et al
JCP
Original Research

ECT for Schizophrenia

April 26, 2017

ECT is effective in patients with schizophrenia who do not respond to clozapine or cannot take it due to adverse effects. This study, conducted in a large sample using...
, ,
JCP
Original Research

Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults

August 26, 2014

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe